Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Receivables - Other (2017 - 2020)

Historic Receivables - Other for Sutro Biopharma (STRO) over the last 4 years, with Q1 2020 value amounting to $6.4 million.

  • Sutro Biopharma's Receivables - Other rose 43905.72% to $6.4 million in Q1 2020 from the same period last year, while for Mar 2020 it was $6.4 million, marking a year-over-year increase of 43905.72%. This contributed to the annual value of $1.0 million for FY2019, which is 948.91% up from last year.
  • According to the latest figures from Q1 2020, Sutro Biopharma's Receivables - Other is $6.4 million, which was up 43905.72% from $1.0 million recorded in Q4 2019.
  • In the past 5 years, Sutro Biopharma's Receivables - Other ranged from a high of $6.4 million in Q1 2020 and a low of $784000.0 during Q4 2017
  • Moreover, its 4-year median value for Receivables - Other was $1.1 million (2019), whereas its average is $1.9 million.
  • Per our database at Business Quant, Sutro Biopharma's Receivables - Other surged by 948.91% in 2019 and then soared by 43905.72% in 2020.
  • Over the past 4 years, Sutro Biopharma's Receivables - Other (Quarter) stood at $784000.0 in 2017, then grew by 22.32% to $959000.0 in 2018, then increased by 9.49% to $1.0 million in 2019, then soared by 509.9% to $6.4 million in 2020.
  • Its Receivables - Other stands at $6.4 million for Q1 2020, versus $1.0 million for Q4 2019 and $2.1 million for Q3 2019.